- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
FDA: Avoid some sexual enhancement supplements
The FDA is warning consumers not to purchase or consume Zimaxx, Libidus, Neophase, Nasutra, Vigor-25, Actra-Rx, or 4EVERON. These products are promoted and sold on Web sites as "dietary supplements" for treating erectile dysfunction (ED) and enhancing sexual performance, but they are in fact illegal drugs that contain potentially harmful undeclared ingredients.
FDA: Avoid some sexual enhancement supplements
The FDA is warning consumers not to purchase or consume Zimaxx, Libidus, Neophase, Nasutra, Vigor-25, Actra-Rx, or 4EVERON. These products are promoted and sold on Web sites as "dietary supplements" for treating erectile dysfunction (ED) and enhancing sexual performance, but they are in fact illegal drugs that contain potentially harmful undeclared ingredients. These products have not been approved by the FDA, and there is no guarantee of their safety and effectiveness or of the purity of their ingredients. The agency advised consumers who have tried any of these products to discontinue use and to consult their healthcare provider. The FDA encourages anyone experiencing ED to seek guidance from a healthcare provider before purchasing a product to treat this medical condition.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Examining Barriers to Care in Diabetic Retinopathy Screening
November 30th 2023Prior research has shown the association between various socioeconomic variables and lower adherence to diabetic retinopathy screening, but few have elaborated on the patient perspective to understand the reason behind this association.
